138 research outputs found

    Dust masses for a large sample of core-collapse supernovae from optical emission line asymmetries: dust formation on 30-year time-scales

    Get PDF
    Modelling the red–blue asymmetries seen in the broad emission lines of core-collapse supernovae (CCSNe) is a powerful technique to quantify total dust mass formed in the ejecta at late times (>5 yr after outburst) when ejecta dust temperatures become too low to be detected by mid-infrared (IR) instruments. Following our success in using the Monte Carlo radiative transfer code DAMOCLES to measure the dust mass evolution in SN 1987A and other CCSNe, we present the most comprehensive sample of dust mass measurements yet made with DAMOCLES, for CCSNe aged between 4 and 60 yr after outburst. Our sample comprises multi-epoch late-time optical spectra taken with the Gemini/Gemini Multi-Object Spectrographs (GMOS) and Very Large Telescope (VLT) X-Shooter spectrographs, supplemented by archival spectra. For the 14 CCSNe that we have modelled, we confirm a dust mass growth with time that can be fit by a sigmoid curve that is found to saturate beyond an age of ∼30 yr, at a mass of 0.23+0.17−0.12 M⊙. For an expanded sample including dust masses found in the literature for a further 11 CCSNe and six CCSN remnants, the dust mass at saturation is found to be 0.42+0.09−0.05 M⊙. Uncertainty limits for our dust masses were determined from a Bayesian analysis using the affine invariant Markov chain Monte Carlo ensemble sampler EMCEE with DAMOCLES. The best-fitting line profile models for our sample all required grain radii between 0.1 and 0.5 μm. Our results are consistent with CCSNe forming enough dust in their ejecta to significantly contribute to the dust budget of the Universe

    Prodrug converting enzyme gene delivery by L. monocytogenes

    Get PDF
    <p>Abstract</p> <p>Background</p> <p><it>Listeria monocytogenes </it>is a highly versatile bacterial carrier system for introducing protein, DNA and RNA into mammalian cells. The delivery of tumor antigens with the help of this carrier into tumor-bearing animals has been successfully carried out previously and it was recently reported that <it>L. monocytogenes </it>is able to colonize and replicate within solid tumors after local or even systemic injection.</p> <p>Methods</p> <p>Here we report on the delivery of two prodrug converting enzymes, purine-deoxynucleoside phosphorylase (PNP) and a fusion protein consisting of yeast cytosine deaminase and uracil phosphoribosyl transferase (FCU1) into cancer cells in culture by <it>L. monocytogenes</it>. Transfer of the prodrug converting enzymes was achieved by bacterium mediated transfer of eukaryotic expression plasmids or by secretion of the proteins directly into the host cell cytosol by the infecting bacteria.</p> <p>Results</p> <p>The results indicate that conversion of appropriate prodrugs to toxic drugs in the cancer cells occured after both procedures although <it>L. monocytogenes</it>-mediated bactofection proved to be more efficient than enzyme secretion 4T1, B16 and COS-1 tumor cells. Exchanging the constitutively P<sub>CMV</sub>-promoter with the melanoma specific P<sub>4xTETP</sub>-promoter resulted in melanoma cell-specific expression of the prodrug converting enzymes but reduced the efficiencies.</p> <p>Conclusion</p> <p>These experiments open the way for bacterium mediated tumor specific activation of prodrugs in live animals with tumors.</p

    E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954

    Get PDF
    Prodrug activation gene therapy is a developing approach to cancer treatment, whereby prodrug-activating enzymes are expressed in tumour cells. After administration of a non-toxic prodrug, its conversion to cytotoxic metabolites directly kills tumour cells expressing the activating enzyme, whereas the local spread of activated metabolites can kill nearby cells lacking the enzyme (bystander cell killing). One promising combination that has entered clinical trials uses the nitroreductase NfsB from Escherichia coli to activate the prodrug, CB1954, to a potent bifunctional alkylating agent. NfsA, the major E. coli nitroreductase, has greater activity with nitrofuran antibiotics, but it has not been compared in the past with NfsB for the activation of CB1954. We show superior in vitro kinetics of CB1954 activation by NfsA using the NADPH cofactor, and show that the expression of NfsA in bacterial or human cells results in a 3.5- to 8-fold greater sensitivity to CB1954, relative to NfsB. Although NfsB reduces either the 2-NO2 or 4-NO2 positions of CB1954 in an equimolar ratio, we show that NfsA preferentially reduces the 2-NO2 group, which leads to a greater bystander effect with cells expressing NfsA than with NfsB. NfsA is also more effective than NfsB for cell sensitisation to nitrofurans and to a selection of alternative, dinitrobenzamide mustard (DNBM) prodrugs

    Study Protocol - Accurate assessment of kidney function in Indigenous Australians: aims and methods of the eGFR Study

    Get PDF
    Background: There is an overwhelming burden of cardiovascular disease, type 2 diabetes and chronic kidney disease among Indigenous Australians. In this high risk population, it is vital that we are able to measure accurately kidney function. Glomerular filtration rate is the best overall marker of kidney function. However, differences in body build and body composition between Indigenous and non-Indigenous Australians suggest that creatinine-based estimates of glomerular filtration rate derived for European populations may not be appropriate for Indigenous Australians. The burden of kidney disease is borne disproportionately by Indigenous Australians in central and northern Australia, and there is significant heterogeneity in body build and composition within and amongst these groups. This heterogeneity might differentially affect the accuracy of estimation of glomerular filtration rate between different Indigenous groups. By assessing kidney function in Indigenous Australians from Northern Queensland, Northern Territory and Western Australia, we aim to determine a validated and practical measure of glomerular filtration rate suitable for use in all Indigenous Australians

    Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer

    Get PDF

    Design of prodrugs for suicide gene therapy.

    No full text

    Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+metastatic breast cancer

    No full text
    Roche Holding AG, and its subsidiaries Genentech Inc and Chugai Pharmaceutical Co Ltd, are developing trastuzumab emtansine (trastuzumab-DM1) for the treatment of HER2+ metastatic breast cancer. Trastuzumab emtansine is a tumor-activated prodrug resulting from the conjugation of the humanized anti-HER2 mAb trastuzumab, which has been used in the treatment of breast cancer for over 10 years, with ImmunoGen Inc's cytotoxic and antimitotic maytansine derivative DM1. The maytansinoids bind microtubules in a manner similar to the vinca alkaloids; however, maytansinoids have been recognized to be 20- to 100-fold more potent at blocking mitosis. Nevertheless, the use of these compounds as single agents is limited by toxicity. By conjugating DM1 with trastuzumab, the delivery of the cytotoxic agent to target cells is more specific and reduces the safety concerns. In preclinical studies, the conjugation was effective in breast cancer cell lines resistant to trastuzumab, and demonstrated complete tumor regression in SCID mice bearing KPL4 breast cancer xenografts. Clinically, trastuzumab emtansine exhibited efficacy in patients with HER2+ metastatic breast cancer who had progressed on previous chemotherapy regimens or with trastuzumab therapy. Furthermore, preclinical studies have reported that trastuzumab emtansine potentiates the effect of a number of chemotherapeutic agents (including carboplatin, 5-fluorouracil and docetaxel), other antibodies, receptor tyrosine kinase inhibitors and PI3K inhibitors, and many of these combinations are set to be tested in humans. Trastuzumab emtansine offers an exciting new option for the treatment of patients with refractory, metastatic breast cancer
    • …
    corecore